| Lipid Composition for FAGG-201 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.975 | 0.78 | 65 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-202 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.900 | 0.72 | 60 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.075 | 0.06 | 5 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-203 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.750 | 0.60 | 50 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.225 | 0.18 | 15 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-204 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.600 | 0.48 | 40 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.375 | 0.29 | 25 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAGG-205 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.450 | 0.36 | 30 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.525 | 0.41 | 35 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAGG-206 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.300 | 0.24 | 20 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.675 | 0.53 | 45 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAGG-207 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.150 | 0.12 | 10 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.825 | 0.65 | 55 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAGG-208 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.075 | 0.06 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.900 | 0.71 | 60 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.075 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAGG-209 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.0375 | 0.03 | 2.5 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.9375 | 0.74 | 62.5 |
| Cholesterol | 0.4350 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.0750 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.0150 | 0.01 | 1 |
| Total | 1.5000 µmol/vial | 1.16 mg/vial | 100 |
| Lipid Composition for FAGG-210 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.015 | 0.01 | 1 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.960 | 0.75 | 64 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.15 mg/vial | 100 |
| Lipid Composition for FAGG-211 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.975 | 0.78 | 65 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
| Lipid Composition for FAGG-212 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.900 | 0.72 | 60 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.075 | 0.06 | 5 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
| Lipid Composition for FAGG-213 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.750 | 0.60 | 50 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.225 | 0.18 | 15 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
| Lipid Composition for FAGG-214 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.600 | 0.48 | 40 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.375 | 0.29 | 25 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-215 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.450 | 0.36 | 30 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.525 | 0.41 | 35 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-216 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.300 | 0.24 | 20 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.675 | 0.53 | 45 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-217 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.150 | 0.12 | 10 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.825 | 0.65 | 55 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-218 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.075 | 0.06 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.900 | 0.71 | 60 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-219 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.0375 | 0.03 | 2.5 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.9375 | 0.74 | 62.5 |
| Cholesterol | 0.4350 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.0750 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.0150 | 0.02 | 1 |
| Total | 1.5000 µmol/vial | 1.17 mg/vial | 100 |
| Lipid Composition for FAGG-220 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | 0.015 | 0.01 | 1 |
| 1,2-dioleoyl-sn-glycero-3-phosphocholine | 0.960 | 0.75 | 64 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)- 2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
